Research Article| Volume 3, ISSUE 3, P238-245, July 2012

Comparison of scoring methods for ACE-27: Simpler is better

Published:February 27, 2012DOI:



      To examine the prognostic value of different comorbidity coding schemes for predicting survival of newly diagnosed elderly cancer patients.

      Materials and methods

      We analyzed data from 8867 patients aged 65 years of age or older, newly diagnosed with cancer. Comorbidities present at the time of diagnosis were collected using the Adult Comorbidity Evaluation-27 index (ACE-27). We examined multiple scoring schemes based on the individual comorbidity ailments, and their severity rating. Harrell's c index and Akaike Information Criterion (AIC) were used to evaluate the performance of the different comorbidity models.


      Comorbidity led to an increase in c index from 0.771 for the base model to 0.782 for a model that included indicator variables for every ailment. The prognostic value was however much higher for prostate and breast cancer patients. A simple model which considered linear scores from 0 to 3 per ailment, controlling for cancer type, was optimal according to AIC.


      The presence of comorbidity impacts on the survival of elderly cancer patients, especially for less lethal cancers, such as prostate and breast cancers. Different ailments have different impacts on survival, necessitating the use of different weights per ailment in a simple summary score of the ACE-27.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Piccirillo J.F.
        • Feinstein A.R.
        Clinical symptoms and comorbidity: significance for the prognostic classification of cancer.
        Cancer. 1996 Mar 1; 77: 834-842
        • Read W.L.
        • Tierney R.M.
        • Page N.C.
        • Costas I.
        • Govindan R.
        • Spitznagel E.L.
        • et al.
        Differential prognostic impact of comorbidity.
        J Clin Oncol. 2004 Aug 1; 22: 3099-3103
      1. Surveillance Epidemiology and End Results (SEER) program.
        SEER Stat Fact Sheets. 2009
        • Satariano W.A.
        Comorbidities and cancer.
        in: Hunter C.P. Johnson K.A. Muss H.B. Cancer in the elderly. 1st ed. Marcel Dekker, New York2000: 477-499
        • Albertsen P.C.
        • Fryback D.G.
        • Storer B.E.
        • Kolon T.F.
        • Fine J.
        The impact of co-morbidity on life expectancy among men with localized prostate cancer.
        J Urol. 1996 Jul; 156: 127-132
        • Yancik R.
        • Wesley M.N.
        • Ries L.G.
        • Havlik R.J.
        • Long S.
        • Edwards B.K.
        • et al.
        Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients—a population-based study.
        Cancer. 1998 Jun 1; 82: 2123-2134
        • Smith A.W.
        • Reeve B.B.
        • Bellizzi K.M.
        • Harlan L.C.
        • Klabunde C.N.
        • Amsellem M.
        • et al.
        Cancer, comorbidities, and health-related quality of life of older adults.
        Health Care Financ Rev. 2008; 29: 41-56
        • Bellizzi K.M.
        • Mustian K.M.
        • Palesh O.G.
        • Diefenbach M.
        Cancer survivorship and aging: moving the science forward.
        Cancer. 2008 Dec 15; 113: 3530-3539
        • Piccirillo J.F.
        • Vlahiotis A.
        • Barrett L.B.
        • Flood K.L.
        • Spitznagel E.L.
        • Steyerberg E.W.
        The changing prevalence of comorbidity across the age spectrum.
        Crit Rev Oncol Hematol. 2008 Aug; 67: 124-132
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Extermann M.
        Measurement and impact of comorbidity in older cancer patients.
        Crit Rev Oncol Hematol. 2000 Sep; 35: 181-200
        • Colinet B.
        • Bertrand D.
        • Lacombe S.
        • Bozonnat M.C.
        • Daures J.P.
        • Pujol J.L.
        • et al.
        A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.
        Br J Cancer. 2005 Nov 14; 93: 1098-1105
        • Kaplan M.H.
        • Feinstein A.R.
        The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.
        J Chronic Dis. 1974; 27: 387-404
        • Piccirillo J.F.
        • Tierney R.M.
        • Costas I.
        • Grove L.
        • Spitznagel Jr., E.L.
        Prognostic importance of comorbidity in a hospital-based cancer registry.
        JAMA. 2004 May 26; 291: 2441-2447
        • Johnston A.S.
        • Piccirillo J.F.
        • Creech C.M.
        • Littenberg B.
        • Jeffe D.
        • Spitznagel E.L.J.
        Validation of a comorbidity education program.
        J Registry Manag. 2001; 28: 125-131
        • Akaike H.
        A new look at the statistical model identification.
        IEEE Trans Autom Control. 1974; 19: 716-723
        • Steyerberg E.W.
        Clinical prediction models: a practical approach to development, validation, and updating.
        Statistics for Biology and Health, Springer New York2009
        • Harrell F.E.
        • Lee K.L.
        • Mark D.B.
        Tutorials in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
        Stat Med. Feb 28 1996; 15: 361-387
        • Piccirillo J.F.
        • Creech C.M.
        • Zequeira R.
        • Anderson S.
        • Johnston A.S.
        Inclusion of comorbidity into oncology data registries.
        J Registry Manag. 1999; 26: 66-70
        • Coebergh JW M.L.
        • Post P.N.
        • Razenberg P.P.
        Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996.
        J Clin Epidemiol. 1999 Dec; 52: 1131-1136
        • Sundarajan V.
        • Quan H.
        • Halfon P.
        • Fushimi K.
        • Luthi J.C.
        • Burnand B.
        • et al.
        Cross-national comparative performance of three versions of the ICD-10 Charlson index.
        Med Care. 2007; 45: 1210-1215
        • Cleves M.A.
        • Sanchez N.
        • Draheim M.
        Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data.
        J Clin Epidemiol. 1997; 50: 903-908
        • Ghali W.A.
        • Hall R.E.
        • Rosen A.K.
        • Ash A.S.
        • Moskowitz M.A.
        Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data.
        J Clin Epidemiol. 1996; 49: 273-278
        • D'Hoore W.
        • Bouckaert A.
        • Tilquin C.
        Practical considerations on the use of the Charlson comorbidity index with administrative data bases.
        J Clin Epidemiol. 1996; 49: 1429-1433
        • Fang A.
        • Piccirillo J.F.
        A comparison of the claims-based ICD-9-CM and the chart-based approaches to classifying comorbidity and complications by hospital-based cancer registrars.
        J Registry Manag. 2006; 33: 10-16
        • Wells C.K.
        • Stoller J.K.
        • Feinstein A.R.
        • Horwitz R.I.
        Comorbid and clinical determinants of prognosis in endometrial cancer.
        Arch Intern Med. 1984; 144: 2004-2009
        • Satariano W.A.
        • Ragland D.R.
        The effect of comorbidity on 3-year survival of women with primary breast cancer.
        Ann Intern Med. 1994; 120: 104-110
        • Stukenborg G.J.
        • Wagner D.P.
        • Connors A.F.J.
        Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations.
        Med Care. 2001 Jul; 39: 727-739
        • Elixhauser A.
        • Steiner C.
        • Harris R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619
        • Wang C.Y.
        • Baldwin L.M.
        • Saver B.G.
        • Dobie S.A.
        • Green P.K.
        • Cai Y.
        • et al.
        The contribution of longitudinal comorbidity measurements to survival analysis.
        Med Care. 2009; 47: 813-820
        • Yung K.C.
        • Piccirillo J.F.
        The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.
        Arch Otolaryngol Head Neck Surg. 2008 Oct; 134: 1045-1049